Abstract
Pharmacogenomics makes use of genetic and genomic principles to facilitate drug discovery and development, and to improve drug therapy. Its goal is to attain optimal therapy for the individual patient. This article analyzes current trends in pharmacogenomics and asks how this new science affects drug development in the pharmaceutical industry and the clinical use of drugs.
Footnotes
This article also appears in AAPS Newsmagazine, April 2002;5(4)-17,33-35.
References
- 1.Sadee W.Pharmacogenomics Brit. Med. J. 19993191286–1286.10559039 [Google Scholar]
- 2.Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491. doi: 10.1126/science.286.5439.487. [DOI] [PubMed] [Google Scholar]
- 3.Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: The promise of personalized medicine. AAPS Pharm Sci 2000;2 (1) article 4. Available http://www.pharmsci.org/scientificjournals/pharmsci/journal/4.html [DOI] [PMC free article] [PubMed]
- 4.Johnson JA. Drug targe pharmacogenomics. Am J Pharmacogenomics. 2001;1:271–281. doi: 10.2165/00129785-200101040-00004. [DOI] [PubMed] [Google Scholar]
- 5.Tolle R. Information technology tools for efficient SNP studies. Am J Pharmacogenomics. 2001;1:303–314. doi: 10.2165/00129785-200101040-00007. [DOI] [PubMed] [Google Scholar]
- 6.Cambien F, Poirier O, Nicaud V, et al. Sequence diversity in 36 candidate genes for cardiovascular disease. Am J Hum Genet. 1999;65:183–191. doi: 10.1086/302448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Phillips KA, Veenstra D, Sadee W. Implications of the genetic revolution for health services research: Pharmacogenomics and improvements in drug therapy. Health Serv Res. 2000;35:128–140. [PMC free article] [PubMed] [Google Scholar]
- 8.Krynetsky EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet. 1998;63:11–16. doi: 10.1086/301941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200–1205. doi: 10.1001/jama.279.15.1200. [DOI] [PubMed] [Google Scholar]
- 10.Phillips KA, Veenstra DL, Oren E, Lee K, Sadee W. The potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA. 2001;286:2270–2279. doi: 10.1001/jama.286.18.2270. [DOI] [PubMed] [Google Scholar]
- 11.Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. NEJM. 1998;338:86–93. doi: 10.1056/NEJM199801083380203. [DOI] [PubMed] [Google Scholar]
- 12.Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. PNAS. 2000;97:10483–10488. doi: 10.1073/pnas.97.19.10483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615–1616. doi: 10.1016/S0140-6736(00)02221-2. [DOI] [PubMed] [Google Scholar]
- 14.Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature. 2000;411:199–204. doi: 10.1038/35075590. [DOI] [PubMed] [Google Scholar]
- 15.Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high resolution scanning of human chromosome 21. Science. 2001;294:1719–1723. doi: 10.1126/science.1065573. [DOI] [PubMed] [Google Scholar]